Currently, there are 86.12M common shares owned by the public and among those 86.06M shares have been available to trade.
The company’s stock has a 5-day price change of -16.75% and 15.76% over the past three months. COGT shares are trading 69.90% year to date (YTD), with the 12-month market performance up to 17.39% higher. It has a 12-month low price of $3.67 and touched a high of $12.61 over the same period. COGT has an average intraday trading volume of 923.86K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.01%, -9.94%, and 17.39% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cogent Biosciences Inc (NASDAQ: COGT) shares accounts for 90.13% of the company’s 86.12M shares outstanding.
It has a market capitalization of $1.09B and a beta (3y monthly) value of 1.81. The earnings-per-share (ttm) stands at -$2.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.07% over the week and 6.36% over the month.
Earnings per share for the fiscal year are expected to increase by 4.11%, and 0.98% over the next financial year.
Looking at the support for the COGT, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on February 26, 2024, with the firm’s price target at $14-$8. Citigroup coverage for the Cogent Biosciences Inc (COGT) stock in a research note released on February 08, 2024 offered a Buy rating with a price target of $11. Wedbush was of a view on December 11, 2023 that the stock is Neutral, while JP Morgan gave the stock Overweight rating on December 08, 2023, issuing a price target of $18. Robert W. Baird on their part issued Outperform rating on April 28, 2023.
